An investment case for maternal and neonatal tetanus elimination

被引:4
作者
Laing, Sarah K. [1 ]
Griffiths, Ulla [2 ]
Raza, Azhar Abid [2 ]
Zulu, Flint [2 ]
Yakubu, Ahmadu [3 ]
Bessias, Sophia [4 ]
Ozawa, Sachiko [5 ,6 ]
机构
[1] Duke Univ, Duke Global Hlth Inst, Durham, NC USA
[2] UNICEF, Hlth Sect, New York, NY USA
[3] UNICEF, Immunizat Coverage & Equ, New York, NY USA
[4] Univ N Carolina, Enterprise Analyt & Data Sci, Hlth Care, Chapel Hill, NC 27515 USA
[5] Univ N Carolina, Div Practice Adv & Clin Educ, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA
[6] Univ N Carolina, Dept Maternal & Child Hlth, UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA
关键词
Tetanus; Maternal child health; Neonatal mortality; Vaccination; Elimination; Cost-effectiveness; COST-EFFECTIVENESS; NEWBORN BABIES; HEALTH-CARE; IMMUNIZATION; INTERVENTIONS; PREVENTION; STRATEGIES; DELIVERY;
D O I
10.1016/j.vaccine.2019.11.052
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Globally, 13 countries have yet to eliminate maternal and neonatal tetanus. While efforts have improved access to tetanus toxoid containing vaccines (TTCVs) and increased clean delivery practices, reaching elimination targets (<1 case of neonatal tetanus per 1000 live births per district per year) may require significant resources to reach the remaining high risk and hard-to-reach districts. Methods: We estimated the cost to achieve maternal and neonatal tetanus elimination (MNTE) in three years in the remaining 13 countries: Afghanistan, Angola, Central African Republic, Democratic Republic of the Congo, Guinea, Mali, Nigeria, Pakistan, Papua New Guinea, Somalia, South Sudan, Sudan, and Yemen. Costs were estimated for: (1) vaccination campaigns using standard TTCVs and TT-Uniject (TM) targeting women of reproductive age in high risk areas, (2) additional vaccinations delivered to pregnant women at antenatal care (ANC) clinics, (3) clean delivery and umbilical cord care promotion, (4) neonatal tetanus surveillance strengthening, and (5) validation activities. We forecasted the averted mortality to assess the cost-effectiveness of achieving MNTE. Results: It will cost an estimated US$197.7 million to realize MNTE over three years. These costs include $161.4 million for vaccination campaigns, $6.1 million for routine vaccination during ANC, $23.3 million for promotion of clean delivery practices, $4 million for surveillance, and $3 million for validation of MNTE. Achieving MNTE will avert approximately 70,000 neonatal deaths over ten years of vaccine protection, resulting in approximately 4.4 million life years gained. It will cost $2,900 per death averted and $45 per life year gained. Conclusion: Maternal and neonatal tetanus can be eliminated with significant financial investment, high prioritization, and strong political will. While substantial costs must be incurred to reach hard-to-reach populations, MNTE should be accomplished as a matter of health equity, and will significantly contribute to reaching the United Nations' Sustainable Development Goals. (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2241 / 2249
页数:9
相关论文
共 50 条
[31]   Neonatal tetanus in Casablanca [J].
Nejjari, N ;
Allali, B ;
Bouharrou, A ;
Habzi, A ;
Najdi, T ;
Lahbabi, S ;
Benomar, S .
MEDECINE ET MALADIES INFECTIEUSES, 2002, 32 (05) :223-227
[32]   Investment case concepts in leprosy elimination: A systematic review [J].
Tiwari, Anuj ;
Richardus, Jan Hendrik .
LEPROSY REVIEW, 2016, 87 (01) :2-22
[33]   Prognostic factors in neonatal tetanus [J].
Davies-Adetugbo, AA ;
Torimiro, SEA ;
Ako-Nai, KA .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 1998, 3 (01) :9-13
[34]   Protective effects of topical antimicrobials against neonatal tetanus [J].
Bennett, J ;
Macia, J ;
Traverso, H ;
Banoagha, S ;
Malooly, C ;
Boring, J .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1997, 26 (04) :897-903
[35]   Maternal disease factors associated with neonatal jaundice: a case-control study [J].
Yu, Youngjae ;
Choi, Jinwha ;
Lee, Myeong Hoon ;
Kim, KangHyun ;
Ryu, Hyun Mee ;
Han, Hyun Wook .
BMC PREGNANCY AND CHILDBIRTH, 2022, 22 (01)
[36]   Global hepatitis C elimination: an investment framework [J].
Pedrana, Alisa ;
Howell, Jessica ;
Scott, Nick ;
Schroeder, Sophia ;
Kuschel, Christian ;
Lazarus, Jeffrey, V ;
Atun, Rifat ;
Baptista-Leite, Ricardo ;
t'Hoen, Ellen ;
Hutchinson, Sharon J. ;
Aufegger, Lisa ;
Peck, Raquel ;
Sohn, Annette H. ;
Swan, Tracy ;
Thursz, Mark ;
Lesi, Olufunmilayo ;
Sharma, Manik ;
Thwaites, John ;
Wilson, David P. ;
Hellard, Margaret .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (10) :927-939
[37]   Risk factor for neonatal tetanus in West Burkina Faso: A case control study [J].
Roisin, AJ ;
Prazuck, T ;
Tall, F ;
Sanou, J ;
Cot, M ;
Ballereau, FV .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1996, 12 (05) :535-537
[38]   Eliminating Maternal and Neonatal Tetanus and Promoting Clean Delivery Practices Through Disposable Clean Birth Kits [J].
Raza, Syed Ahsan ;
Avan, Bilal Iqbal .
FRONTIERS IN PUBLIC HEALTH, 2019, 7
[39]   Global Health Ethics: The Case of Maternal and Neonatal Survival [J].
Anderson, Frank W. J. ;
Johnson, Timothy R. B. ;
de Vries, Raymond .
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2017, 43 :125-135
[40]   Dynamic linear models for policy monitoring. The case of maternal and neonatal mortality in Ghana [J].
Adebanji, Atinuke ;
Insua, David Rios ;
Ruggeri, Fabrizio .
SOCIO-ECONOMIC PLANNING SCIENCES, 2022, 83